



AstraZeneca BioVentureHub

A unique innovation platform for collaborations and growth within the life science industry

Ulrika Edvardsson, Managing Director AZ BioVentureHub

TIM Think Tank, 2024-04-16



A unique initiative of Open Innovation within AstraZeneca



- *Established 2015*
- *The sharing economy applied to life science*
- *Scale-up focus*
- *Sector convergence*
- *Non-competitive synergies*
- *Public-Private-Partnership innovation model (governmental and regional funding)*



- 1** Strengthen the life science ecosystem
- 2** Support SME growth
- 3** Attract talents to the region

Generating value – SME highlights 2023*

- 3** new companies/groups
- 48** new employees
- 52** new consultants
- 1.08** BSEK capital raised
- 6** new products launched
- 12** new products via licensing of BVH company technology
- 33** new patents
- 3** clinical studies initiated
- 23** peer reviewed publications



Key features and success factors

Advanced research infrastructure

Unparalleled access to a vibrant R&D site and AstraZeneca's cutting-edge labs and facilities.



Expertise and mentorship

Unique mentorship opportunities with AstraZeneca's scientists and experts.



Collaboration opportunities

The hub catalyses opportunities for collaborations with AstraZeneca and the broader community.



“Dare to Share” community

Connects members to a dynamic network where collaboration and knowledge sharing thrive.



Portfolio strategy

Sector convergence & non-competitive synergies.



Proximity

Physical presence. “Innovation is a contact sport”



No strings attached

AstraZeneca has no rights - not even “rights of first refusal”



Contact details:

Ulrika Edvardsson, PhD

Senior Director & Managing Director AZ BioVentureHub

AstraZeneca

AZ BioVentureHub AB


Pepparedsleden 1, SE-431 83 Mölndal, Sweden

T: +46 (0)31 7763543 M: +46 (0)706 234868

ulrika.edvardsson@astrazeneca.com



azbioventurehub.com



bioventurehub@astrazeneca.com



@bioventurehub



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com

